###begin article-title 0
###xml 83 87 <span type="species:ncbi:10090">Mice</span>
Functional Deficits in nNOSmu-Deficient Skeletal Muscle: Myopathy in nNOS Knockout Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: JP PG SCF. Performed the experiments: JP KNEA. Analyzed the data: JP KNEA PG SCF. Contributed reagents/materials/analysis tools: JSC. Wrote the paper: JP SCF.
###end p 1
###begin p 2
Current address: Baker Heart Research Institute, Melbourne, Australia
###end p 2
###begin p 3
###xml 681 688 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 916 923 913 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
###xml 1112 1116 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
Skeletal muscle nNOSmu (neuronal nitric oxide synthase mu) localizes to the sarcolemma through interaction with the dystrophin-associated glycoprotein (DAG) complex, where it synthesizes nitric oxide (NO). Disruption of the DAG complex occurs in dystrophinopathies and sarcoglycanopathies, two genetically distinct classes of muscular dystrophy characterized by progressive loss of muscle mass, muscle weakness and increased fatigability. DAG complex instability leads to mislocalization and downregulation of nNOSmu; but this is thought to play a minor role in disease pathogenesis. This view persists without knowledge of the role of nNOS in skeletal muscle contractile function in vivo and has influenced gene therapy approaches to dystrophinopathy, the majority of which do not restore sarcolemmal nNOSmu. We address this knowledge gap by evaluating skeletal muscle function in nNOS knockout (KN1) mice using an in situ approach, in which the muscle is maintained in its normal physiological environment. nNOS-deficiency caused reductions in skeletal muscle bulk and maximum tetanic force production in male mice only. Furthermore, nNOS-deficient muscles from both male and female mice exhibited increased susceptibility to contraction-induced fatigue. These data suggest that aberrant nNOSmu signaling can negatively impact three important clinical features of dystrophinopathies and sarcoglycanopathies: maintenance of muscle bulk, force generation and fatigability. Our study suggests that restoration of sarcolemmal nNOSmu expression in dystrophic muscles may be more important than previously appreciated and that it should be a feature of any fully effective gene therapy-based intervention.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 179 182 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Stamler1">[1]</xref>
###xml 184 187 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Silvagno1">[2]</xref>
###xml 353 356 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Stamler1">[1]</xref>
###xml 358 361 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Kobzik1">[3]</xref>
###xml 362 365 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Thomas2">[7]</xref>
###xml 375 383 374 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 638 641 637 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Stamler1">[1]</xref>
###xml 643 646 642 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Kobzik1">[3]</xref>
###xml 647 650 646 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Eu1">[5]</xref>
###xml 720 728 719 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 737 740 736 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Eu1">[5]</xref>
###xml 829 836 828 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Nitric oxide (NO) is a versatile signaling molecule in skeletal muscle and is synthesized from oxygen and L-arginine by muscle-specific neuronal nitric oxide synthase mu (nNOSmu) [1], [2]. Functions of NO in muscle include: attenuation of muscle force generation and regulation of appropriate blood and oxygen delivery to active muscles during exercise [1], [3]-[7]. However in vitro studies of the role of nitric oxide in contractile function of excised muscles in perfusion baths have generated conflicting results. NO has been reported to increase force-generating capacity of skeletal muscle in some studies and decrease it in others [1], [3]-[5]. This has led to questioning of the physiological relevance of these in vitro studies [5]. These data suggest that the effects of nNOS on the force-generating capacity of muscle in vivo remain to be determined.
###end p 5
###begin p 6
###xml 220 223 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Brenman1">[8]</xref>
###xml 225 228 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Brenman2">[9]</xref>
###xml 518 521 515 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Brenman1">[8]</xref>
###xml 523 527 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Chao1">[10]</xref>
###xml 529 533 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Crosbie1">[11]</xref>
###xml 928 932 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Sander1">[12]</xref>
###xml 934 938 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Asai1">[13]</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
Particular interest in nNOSmu function in skeletal muscle arises from studies of human muscular dystrophies. nNOSmu is localized to the sarcolemma by interaction with the dystrophin-associated glycoprotein (DAG) complex [8], [9]. Disruption of the DAG complex results in decreased nNOSmu expression and aberrant localization. DAG complex disruption occurs in several distinct dystrophies, including Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy and Limb Girdle Muscular Dystrophies (LGMD) 2C, 2D and 2E [8], [10], [11]. These muscle diseases vary in severity and are characterized by progressive loss of muscle bulk, weakness and increased susceptibility to fatigue. Each disease is characterized by defects in nNOSmu expression and/or targeting. Indeed, DMD patients exhibit defective inhibition of vasoconstriction during exercise causing functional muscle ischemia that may exacerbate dystrophic muscle damage [12], [13]. These studies suggest that loss of nNOSmu may contribute to disease pathogenesis.
###end p 6
###begin p 7
###xml 219 226 217 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 236 244 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 395 398 392 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Kobzik1">[3]</xref>
###xml 400 403 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Reid1">[4]</xref>
###xml 722 725 718 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdx</italic>
###xml 745 749 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Gregorevic2">[30]</xref>
###xml 751 755 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Yue1">[31]</xref>
###xml 962 969 957 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 726 731 <span type="species:ncbi:10090">mouse</span>
Although aberrant nNOSmu localization and expression is a feature of the pathology of DMD, BMD and several LGMDs, it is not known whether the loss of nNOSmu can cause contractile deficits in normal or dystrophic muscle in vivo. Indeed, in vitro studies of NO regulation of muscle contractility suggest that nNOSmu-deficiency may actually enhance the force generating capacity of skeletal muscle [3], [4]. This thinking has influenced the development of gene-therapy based therapeutic approaches to treating dystrophin-deficient muscles of DMD patients. Viral-mediated delivery of micro- or mini-dystrophin constructs substantially improves dystrophic pathology without restoring nNOSmu expression at the sarcolemma in the mdx mouse model of DMD [30], [31]. Whether this is a significant limitation of the gene-therapy-based approach remains to be established. It could be a significant limitation if nNOSmu-deficient skeletal muscles exhibit functional deficits in vivo.
###end p 7
###begin p 8
###xml 135 142 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 305 312 303 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 750 758 746 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1439 1443 1431 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
In order to determine if the absence of nNOSmu negatively impacts skeletal muscle function, we evaluated the force-generating capacity in situ of tibialis anterior (TA) muscles from nNOS knockout (KN1) mice. Given the reported effects of nNOSmu on blood supply during exercise, it was important to use an in situ approach where the TA muscle was maintained in the most physiologically relevant state with normal vascularization. Unexpectedly, nNOSmu-deficient muscles from male mice were smaller in mass and generated significantly lower maximum isometric force compared with littermate controls. Moreover, muscles from both male and female mice lacking nNOSmu show increased susceptibility to fatigue compared with controls. In contrast to previous in vitro studies, our data suggest that nNOSmu-deficiency results in reduced force-generating capacity and that NO is necessary for sustained muscle contractility. These data also suggest the possibility that mini- and micro-dystrophins capable of restoring sarcolemmal nNOSmu expression may be more effective at reversing the functional deficits of dystrophic skeletal muscle. The combination of reduced bulk and impaired contractile function lead us to conclude that nNOSmu-deficient muscles are myopathic and that aberrant nNOSmu expression could contribute to functional deficits, especially increased susceptibility to fatigue, in DMD, BMD and LGMD 2C, 2D and 2E. We propose that the NOS1 gene be considered a novel candidate for skeletal muscle myopathies.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 64 68 <span type="species:ncbi:10090">Mice</span>
Sex-Specific Decrease in Skeletal Muscle Bulk of nNOS-Deficient Mice
###end title 10
###begin p 11
###xml 0 11 0 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prima facie</italic>
###xml 214 223 214 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1A</xref>
###xml 533 542 533 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1A</xref>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
Prima facie, the most striking phenotypic characteristic of the nNOS mutant KN1 mice was the reduced body mass of males. Wild type males were on average 6 g heavier than their sex- and age-matched KN1 littermates (Figure 1A). Heterozygous mice appeared similar to wild type mice (data not shown). The well-established sexual dimorphism in body weight was evident from the significantly larger body masses of wild type males relative to wild type females. In contrast, the absence of nNOS did not impact the body mass of KN1 females (Figure 1A). Male mice are unable to achieve normal size in the absence of nNOS.
###end p 11
###begin title 12
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Sex-specific reductions in body and skeletal muscle mass in nNOS-deficient mice.
###end title 12
###begin p 13
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
The body masses of 8 week old adult male (M) and female (F) mice homozygous for the wild type NOS1 allele (+/+) or NOS1 null allele (-/-) are shown in A. The body masses of wild type males are significantly larger (p<0.01) than KN1 littermates and wild type females (p<0.01) (A). The masses of tibialis anterior (TA) muscles from 8 week old adult wild type males are significantly larger (p<0.01) than KN1 male littermates and wild type females (B). The masses of soleus muscles are similarly affected in nNOS mutant mice where KN1 male solei are significantly smaller (p<0.05) than male littermate controls (C). The soleus muscle of wild type males is larger than that of wild type females (p<0.05). Numbers of animals analyzed: 10-11 wild type males, 11 KN1 males, 10-11 wild type females and 12-13 KN1 females. Values shown are mean+/-standard error of the mean (S.E.M).
###end p 13
###begin p 14
###xml 479 488 479 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1B</xref>
###xml 510 519 510 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1C</xref>
###xml 891 907 891 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1B and 1C</xref>
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
###xml 1042 1046 <span type="species:ncbi:10090">mice</span>
Since, skeletal muscle mass accounts for approximately 40-50% of the total body mass of a normal male 8 week old mouse, reductions in skeletal muscle weight could account for the decreased size of the KN1 males. In order to determine the effect of nNOS-deficiency on muscle mass, the wet weights of two hindlimb muscles, the tibialis anterior (a predominantly fast twitch muscle) and soleus muscles (a predominantly slow twitch muscle), were measured. The masses of both the TA (Figure 1B) and soleus muscles (Figure 1C) were significantly decreased in male nNOS mutant mice only, compared with wild type male littermates. Mass reduction occurs in skeletal muscles with different fiber compositions, and therefore could reasonably account for the reduced body mass. In contrast, in female mice, the masses of both TA and soleus muscle were not significantly affected by the absence of nNOS (Figure 1B and 1C, respectively). Together, these data suggest the possibility that nNOS can act as a sex-specific regulator of skeletal muscle mass in mice.
###end p 14
###begin title 15
Decreased Maximum Tetanic Force-Generating Capacity of nNOSmu-Deficient Skeletal Muscle
###end title 15
###begin p 16
###xml 314 322 313 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2</xref>
###xml 404 413 403 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2A</xref>
###xml 596 605 595 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2A</xref>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
The amount of contractile force or tension a given skeletal muscle generates is generally proportional to the mass and length of the muscle itself. Given the reduced TA muscle bulk in male KN1 mice, we tested whether the maximum tetanic force-generating capacity of nNOSmu-deficient TA muscles was also decreased (Figure 2). Maximum tetanic force was significantly decreased in KN1 male TA muscles only (Figure 2A), paralleling the decreases in muscle mass described above. The maximum force-generating capacities of KN1 males, wild type females and KN1 females were not significantly different (Figure 2A). Wild type male TA muscles generated larger tetanic force than those from wild type females. In summary, male nNOSmu-deficient TA muscles are significantly weaker than littermate controls.
###end p 16
###begin title 17
Sex-specific decrease in maximum isometric force-generating capacity in nNOSmu-deficient skeletal muscle.
###end title 17
###begin p 18
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 515 516 514 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
Maximum isometric force output (Po) from TA muscles of 8 week old adult male (M) and female (F) mice homozygous for the wild type NOS1 allele (+/+) or or NOS1 null allele (-/-) is shown in A. Po was significantly decreased (p<0.01) in male KN1 TA muscle compared with sex-matched littermate controls (A). Wild type male mice generated greater total force than wild type female mice (p<0.01). Maximum tetanic force output from female TA skeletal muscle was unaffected by the absence of nNOSmu (A). Specific force (sPo), maximal tetanic force output normalized for the length and mass of the TA muscle, was not significantly affected by the absence of muscle nNOSmu in both males and females (B). Force-frequency profiles for wild type (black circles) and KN1 mice (grey squares) are shown in C. Males and females are pooled into wild type and KN1 groups. There was no difference in the force-frequency curves between KN1 males and their littermate controls suggesting no gross abnormalities in neuromuscular transmission. Numbers of animals analyzed: 15 wild type (8 males and 7 females) and 15 KN1 (7 males and 8 females). Values shown are mean+/-standard error of the mean (S.E.M).
###end p 18
###begin p 19
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 243 244 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 323 332 322 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2B</xref>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
To investigate whether deficits in force production in male KN1 mice could be accounted for by decreased TA mass, we calculated specific force (sPo), the maximal tetanic force output normalized for the cross sectional area of the TA muscle. sPo was not significantly affected by the absence of muscle nNOSmu in either sex (Figure 2B). These data support the argument that decreased force generation in male KN1 TA muscles is most likely due to decreased muscle mass and not to defects in the contractile apparatus.
###end p 19
###begin p 20
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Adams1">[15]</xref>
###xml 386 395 386 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2C</xref>
###xml 631 635 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Adams1">[15]</xref>
nNOS has been reported to regulate the structure and function of the neuromuscular synapse [15]. In order to evaluate the possibility that abnormalities in neuromuscular transmission were contributing to the maximal tetanic force deficit, we evaluated force-frequency curves from wild type and KN1 control males. No significant difference between control and wild type males was found (Figure 2C), suggesting no gross abnormalities in neuromuscular transmission. This is consistent with previously published results where the absence of nNOSmu from postsynaptic folds had only a minor effect on neuromuscular junction transmission [15]. Taken together, the decreased maximum force and unchanged specific force output suggest that the sex-specific reduction in maximal tetanic force in nNOSmu-deficient muscle is most likely due to reduced muscle mass.
###end p 20
###begin title 21
nNOSmu-Deficient Skeletal Muscle Exhibit Increased Susceptibility to Contraction-Induced Fatigue
###end title 21
###begin p 22
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">situ</italic>
###xml 310 317 310 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 387 396 387 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3A</xref>
###xml 538 547 537 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3A</xref>
###xml 757 766 752 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3B</xref>
###xml 1068 1077 1059 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3B</xref>
###xml 1199 1208 1190 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3B</xref>
###xml 1287 1296 1278 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3B</xref>
###xml 1625 1634 1616 1625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g001">Figure 1B</xref>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 1560 1564 <span type="species:ncbi:10090">mice</span>
###xml 1590 1594 <span type="species:ncbi:10090">mice</span>
We then tested the hyopthesis that nNOS deficiency impacts sustained force generation during muscle activity, i.e., the absence of nNOS may decrease resistance to exercise-induced fatigue. In order to test this possibility, TA muscles from KN1 mice were subjected to a simulated exercise protocol in situ (see Methods). Representative data from wild type and KN1 TA muscles are shown in Figure 3A and the averages are presented in 3B. After 40 s of simulated exercise, nNOSmu-deficient muscles begin to show deficits in force production (Figure 3A). By the end of the exercise protocol, the force-generating capacity of KN1 muscle had declined to a significantly lower force plateau (averaging 45.5+/-4.4%) compared with littermate controls (57.8+/-1.7%), (Figure 3B). Note that the trace shown exhibited near normal recovery. These data highlight a marked increase in fatigability of nNOSmu-deficient skeletal muscle. The time taken to fatigue, as represented by the time constant tau, is not significantly different between nNOSmu-deficient TA muscles and controls (Figure 3B). After a 1 minute recovery period, KN1 muscles remain unable to generate normal levels of force compared with controls (Figure 3B). At 5 minutes post-exercise, nNOS-deficient muscles exhibit a full recovery (Figure 3B). Both male and female KN1 TA muscles showed similar enhanced susceptibility to exercise-induced fatigue (data not shown). It is important to note that susceptibility to fatigue was not simply a consequence of reduced muscle mass. TA masses from wild type female mice, male KN1 and female KN1 mice did not differ significantly (Figure 1B), but only nNOS-deficient TAs were more fatigable. These data highlight a novel role for nNOS in regulating sustained force generation during muscle activity.
###end p 22
###begin title 23
nNOSmu-deficient skeletal muscle exhibits decreased resistance to exercise-induced fatigue.
###end title 23
###begin p 24
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
###xml 1163 1167 <span type="species:ncbi:10090">mice</span>
To simulate exercise, TA muscles were maximally stimulated every 2 s for 4 minutes (fatigue period). Force recovery was measured after 1 minute and 5 minutes of rest following the conclusion of the fatigue period. Representative data are shown for wild type (black boxes) and KN1 (grey triangles) and are fitted with exponential decay curves (black for wild type and grey for KN1) (A). Both male and female KN1 mice showed similar patterns of fatigue. During 4 minutes of repeated contraction, nNOSmu-deficient skeletal muscles did not sustain control levels of force (A). Force generation capacity of KN1 mice declined to a significantly lower force plateau (p<0.05) than wild type controls (B). The time taken to fatigue represented by the time constant tau, was not significantly different between wild type and KN1 mice (B). After 1 minute of rest, nNOS-deficient TA muscles did not recover to the same extent as wild type TA muscle (p<0.05). However, after 5 minutes of rest, the force-generating capacity of nNOS-deficient muscles was fully recovered (B). Numbers of animals analyzed: 13 wild type (7 males and 6 females) and 13 KN1 (5 males and 8 females) mice. Values shown in B are mean+/-standard error of the mean (S.E.M).
###end p 24
###begin p 25
###xml 473 474 472 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 601 608 600 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003387-t001">Table 1</xref>
###xml 630 631 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 817 818 815 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 822 823 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 903 910 901 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003387-t001">Table 1</xref>
###xml 955 956 953 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1013 1020 1010 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003387-t001">Table 1</xref>
###xml 1360 1367 1356 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003387-t001">Table 1</xref>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
Next, we addressed potential mechanism(s) of decreased fatigue resistance in nNOSmu-deficient skeletal muscle. We hypothesized that susceptibility to fatigue could be due to increased numbers of fast twitch fibers and fewer slow twitch fibers. Fast twitch fibers have a more glycolytic metabolism and thus fatigue more easily than slow twitch myofibers. A greater proportion of fast twitch fibers would decrease the time taken for the muscle to reach peak twitch tension (Pt) and shorten the relaxation phase. The twitch responses of nNOS-deficient muscles to a single threshold stimulus are shown in Table 1. Peak twitch force (Pt) was significantly reduced in KN1 males compared with controls. Despite this decrease, nNOSmu-deficient muscles did not exhibit any intrinsic weakness, because specific twitch force (sPt, [Pt normalized for cross sectional area]) did not differ from littermate controls (Table 1). However, in contrast to male KN1 muscle, Pt was unaffected by the absence of nNOSmu in female mice (Table 1). KN1 male mice exhibit a sex-specific decrease in Pt, paralleling the decreased TA muscle mass and maximum isometric force deficit. The loss of nNOSmu from skeletal muscle had no significant impact on the time to reach peak tension and the time between maximum and half-maximum force production during the relaxation phase of the twitch (Table 1). The absence of significant difference in the time of the contraction and relaxation phase of the twitch suggest that there is no gross change in the fiber composition of the TA muscle and argue against a fiber type shift as a mechanism for the increased fatigability of nNOSmu-deficient muscle.
###end p 25
###begin title 26
Twitch Properties of nNOSmu-Deficient Skeletal Muscle Fibers.
###end title 26
###begin p 27
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 219 220 219 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
Pt is twitch force. TPT is the time taken to reach peak tension during the contraction phase of the twitch. HRT is the time between maximum and half-maximum force generation during the relaxation phase of the twitch. sPt is specific twitch force. Mean values+/-SEM are shown. double dagger p<0.01, for comparison between wild type and KN1 males. # p<0.01, for comparison between wild type males and females.
###end p 27
###begin p 28
###xml 281 288 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 402 410 401 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g004">Figure 4</xref>
###xml 575 583 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g004">Figure 4</xref>
An alternative possibility was that the decreased resistance to fatigue in KN1 skeletal muscle was caused by an increase in the TA muscle's susceptibility to contraction-induced injury. Therefore we tested whether nNOSmu-deficiency impacts resistance to contraction-induced injury in situ by subjecting TA muscles to a series of consecutive lengthening contractions of progressively increasing strain (Figure 4). We observed no significant difference in resistance to contraction-induced injury between wild type and nNOSmu-deficient TA muscles over a wide range of strains (Figure 4). Thus, the absence of nNOSmu does not affect the susceptibility of the TA to contraction-induced injury. The impaired performance of nNOSmu-deficient skeletal muscle during exercise is unlikely to be due to an increased predisposition to contraction-induced injury.
###end p 28
###begin title 29
nNOSmu-deficiency does not affect the susceptibility of the TA to contraction-induced injury.
###end title 29
###begin p 30
###xml 626 630 <span type="species:ncbi:10090">mice</span>
Contraction-induced injury was produced by subjecting TA muscles to a series of consecutive lengthening contractions of progressively increasing strain. Strain is the percentage increase in length beyond optimal muscle length Lo. Contractile function is expressed as normalized force (force/initial force or P/Pi). The susceptibility to contraction-induced injury for wild type (black squares) and nNOS-deficient (grey diamonds) TA muscles are shown. There was no significant difference between controls and KN1 littermates. Numbers of animals analyzed: 14 wild type (8 males and 6 females) and 11 KN1 (5 males and 6 females) mice. Values shown are mean+/-standard error of the mean (S.E.M).
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 84 91 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 412 416 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 441 447 <span type="species:ncbi:10090">murine</span>
This study provides surprising new insights into nNOSmu function in skeletal muscle in vivo. nNOSmu-deficiency significantly reduces skeletal muscle mass, maximum tetanic force output and fatigue resistance; therefore qualifying the skeletal muscles of KN1 mice as myopathic. Unexpectedly, myopathy is most severe in nNOS-deficient male mice, because female mice exhibit increased fatigability only. Despite the NOS1 gene being localized to murine autosome five, and not on a sex chromosome, the impact of nNOS on skeletal muscle is mediated by unknown sex-specific mechanisms. This emphasizes the importance of considering gender when experimentally assessing nNOS function. Our data suggest that nNOSmu is an important regulator of skeletal muscle size and contractile performance.
###end p 32
###begin p 33
###xml 293 302 291 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g003">Figure 3B</xref>
###xml 639 646 637 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003387-t001">Table 1</xref>
###xml 1085 1088 1077 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Thomas1">[6]</xref>
###xml 1090 1093 1082 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Thomas2">[7]</xref>
###xml 1231 1235 1223 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Sander1">[12]</xref>
###xml 1464 1471 1455 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1633 1637 1624 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Haller1">[18]</xref>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 1452 1455 <span type="species:ncbi:9615">dog</span>
One of the key features of nNOSmu-deficient skeletal muscle is increased susceptibility to fatigue, arguably the most significant new finding of the present study. The force generated by nNOSmu-deficient muscles during simulated exercise plateaus at a significantly lower level than controls (Figure 3B). Recovery appears to occur more gradually in KN1 mice; however there is full restoration of force-generating capacity after a five minute rest period. In order to address potential mechanisms of decreased resistance to fatigue in KN1 mice, we looked for functional evidence of increased numbers of fast twitch fibers in KN1 TA muscle (Table 1). Fast twitch fibers are more easily fatigued than slow twitch fibers. Contraction and relaxation times of single muscle twitches were unaffected by the absence of nNOSmu, arguing that increased fatigability was not due to alterations in the ratio of fast to slow twitch fibers. nNOSmu-derived NO plays an important role in maintaining normal blood supply during exercise by overriding alpha-adrenergic receptor-mediated vasoconstriction [6], [7]. Impaired blood and oxygen delivery to the vascular beds of active muscles can result in repeated muscle exposure to functional ischemia [12]. Therefore we speculate that decreased muscle oxygenation could account, at least in part, for the susceptibility to fatigue of nNOSmu-deficient TA muscles. Additional evidence to support this possibility comes from dog studies in vivo where pharmacological inhibition of nitric oxide synthesis was proposed to cause fatigue by mismatching blood supply with demand in contracting skeletal muscles [18]. Muscle fatigue is a complex physiological process that can occur by many different mechanisms, further studies are required to address the exact mechanism(s) by which nNOS-deficiency results in increased susceptibility of skeletal muscle to fatigue. At present, nNOSmu deficiency does not appear to increase fatigability by significantly altering TA muscle fiber type composition, but may do so through impaired vasoregulatory mechanisms.
###end p 33
###begin p 34
###xml 108 116 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Kobzik1">[3]</xref>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Reid1">[4]</xref>
###xml 389 396 389 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 643 644 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 661 670 660 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003387-g002">Figure 2B</xref>
###xml 1335 1342 1332 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 1539 1543 1536 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Dellorusso1">[17]</xref>
###xml 1987 1995 1983 1991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1995 1998 1991 1994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Eu1">[5]</xref>
###xml 2119 2122 2114 2117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Eu1">[5]</xref>
###xml 2199 2207 2194 2202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2416 2419 2411 2414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Eu1">[5]</xref>
###xml 2476 2483 2471 2478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 2503 2511 2498 2506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2584 2591 2579 2586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 2806 2813 2801 2808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1738 1743 <span type="species:ncbi:10090">mouse</span>
NO has been previously suggested to be an inhibitor of the force-generating capacity of skeletal muscle. In in vitro bath studies on excised muscles, the pharmacological inhibition of NOS results in greater force output [3], [4]. Thus, nitric oxide is widely understood to act as an inhibitor or attenuator of muscle contractility. However, these data are not consistent with our findings in vivo. We find that the absence of nNOSmu is associated with decreased maximal force-generating capacity in males. This is most likely due to decreased muscle mass and not due to defects in the contractile apparatus function; because specific force (sPo) was unchanged (Figure 2B). Similarly, the mass and force-generating capacity of female TA are unaffected by the absence of nNOSmu; therefore the differences between male and female force maximal force generation are likely due to differential impact on muscle mass. Also, inconsistent with the thesis that NO attenuates muscle function, we found that force frequency curves were unaffected by the loss of nNOSmu and the maximum force-generating properties of female muscle were unaffected by the loss of nNOS. In our view, the most likely explanation of the conflicting reports of the impact of NO on contractility is provided by the different experimental approaches employed. We used an in situ approach where the TA muscle is kept in the most physiologically relevant environment possible, within normal physiological temperature range, with intact motor neuron innervation and vasculature [17]. This is very important for evaluating nNOSmu function in muscle due to its known vasoregulatory role. We also circumvented the limitations of pharmacological inhibition of NOS by using the KN1 mouse to specifically inactivate nNOS. Our view is supported by a recent study questioning the physiological relevance of studies designed to address the role of NO in muscle contraction that were conducted on excised muscles in physiological baths in vitro[5]. It was reported that regulation of muscle contractile function by nNOSmu depended dramatically on oxygen concentration [5]. At non-physiological oxygen concentrations, such as those found in excised in vitro muscle preparations, NO inhibited muscle contractility. Conversely, at low physiological oxygen tensions resembling those found in muscle tissue, NO increased the force-generating capacity of skeletal muscle [5]. Our finding that nNOS deficiency results in force loss in situ is consistent with in vitro studies performed under physiological oxygen conditions. Therefore, our in situ methods presumably maintain more physiologically relevant concentrations of oxygen in muscle tissue. In summary, these data suggest that nNOS-derived NO is necessary for maximal force-generating capacity of muscle in vivo and that nNOS plays an important role in the contractile performance of skeletal muscle. Furthermore, these results are consistent with a role of both oxygen and NO in coordinated regulation of the force-generating capacity of skeletal muscle.
###end p 34
###begin p 35
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Haller1">[18]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Haller1">[18]</xref>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 1054 1057 1052 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Brenman1">[8]</xref>
###xml 1059 1063 1057 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Chao1">[10]</xref>
###xml 1065 1069 1063 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Crosbie1">[11]</xref>
###xml 1071 1075 1069 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Chang1">[19]</xref>
###xml 1189 1193 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Chang1">[19]</xref>
###xml 1335 1338 1331 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Thomas1">[6]</xref>
###xml 1340 1343 1336 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Thomas2">[7]</xref>
###xml 1406 1409 1402 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdx</italic>
###xml 1531 1535 1523 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Wehling1">[20]</xref>
###xml 1536 1540 1528 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Brunelli1">[22]</xref>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 1172 1179 <span type="species:ncbi:9606">patient</span>
###xml 1385 1390 <span type="species:ncbi:10090">mouse</span>
###xml 1410 1414 <span type="species:ncbi:10090">mice</span>
###xml 1451 1455 <span type="species:ncbi:10090">mice</span>
###xml 1901 1909 <span type="species:ncbi:9606">patients</span>
###xml 1925 1933 <span type="species:ncbi:9606">patients</span>
The impact of nNOS-deficiency on muscle contractility has implications for two classes of muscle disease: metabolic myopathies and muscular dystrophies. Skeletal muscle fatigue is a common cause of weakness in human myopathies that result from congenital defects in energy metabolism [18]. These muscle diseases often elude diagnosis since symptoms occur predominantly or exclusively during exercise. Often symptoms are simply attributed to a lack of fitness [18]. Since the skeletal muscle phenotype of KN1 mice is consistent with that of human metabolic myopathies, the NOS1 gene may be a novel candidate gene for this class of skeletal muscle disease. The deficiencies in nNOSmu-deficient skeletal muscle are also especially relevant to two types of muscular dystrophy, dystrophinopathies (DMD and BMD) and sarcoglycanopathies (LGMD 2C, LGMD 2D and LGMD 2E), two genetically distinct classes of muscular dystrophy where skeletal muscle nNOSmu expression and localization is dysregulated as a secondary consequence of the disruption of the DAG complex [8], [10], [11], [19]. nNOSmu protein expression is undetectable in cytoplasmic or plasma membrane fractions from DMD patient biopsies [19]. Aberrant nNOSmu activity may contribute to the pathogenesis in DMD and LGMD by impairing blood flow in active muscles resulting in ischemia [6], [7]. Indeed, increased NO bioavailability in mouse models of DMD (mdx mice) and LGMD2D (alpha-sarcoglycan null mice) substantially improves the pathology of dystrophic skeletal muscle tissue [20]-[22]. Our data suggest that specific characteristics of dystrophic pathology, including the inability to maintain muscle bulk, inherent muscle weakness and susceptibility to fatigue may be attributable, at least in part, to defects in nNOS signaling. Our data also raise the intriguing possibility that loss of nNOSmu is more detrimental to muscle function in male patients than in female patients.
###end p 35
###begin p 36
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Gregorevic1">[23]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Watchko1">[26]</xref>
###xml 353 357 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Watchko1">[26]</xref>
###xml 358 362 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Vermeer1">[28]</xref>
###xml 723 727 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Gregorevic1">[23]</xref>
###xml 728 732 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Vermeer1">[28]</xref>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 698 704 <span type="species:ncbi:10090">murine</span>
The pervasive inherent weakness of dystrophin-deficient muscle is due to both increased susceptibility to injury by lengthening contraction and fatigue [23]-[26]. The impaired performance of alpha- and gamma-sarcoglycan-deficient skeletal muscles is also due, at least in part, to increased susceptibility to fatigue, but not contraction-induced injury [26]-[28]. Our data argue against a role for aberrant nNOSmu expression contributing to increased susceptibility to contraction-induced injury, but do suggest the possibility that dysregulation of nNOS signaling provides a mechanism for muscle activity-induced fatigue, a contributing factor to the impaired contractile performance of human and murine dystrophic muscle [23]-[28]. These findings make nNOS signaling pathways relevant to therapeutic approaches to muscular dystrophy.
###end p 36
###begin p 37
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Odom1">[14]</xref>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Odom1">[14]</xref>
###xml 708 711 708 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdx</italic>
###xml 778 782 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Odom1">[14]</xref>
###xml 915 918 914 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdx</italic>
###xml 1056 1060 1055 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Gregorevic1">[23]</xref>
###xml 1061 1065 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Matecki1">[25]</xref>
###xml 1080 1083 1079 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdx</italic>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 1038 1042 <span type="species:ncbi:10090">mice</span>
###xml 1047 1055 <span type="species:ncbi:9606">patients</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
Therapeutic approaches to treating muscular dystrophies must address the progressive loss of muscle mass and extreme muscle weakness. The ideal method to do this is to replace the defective gene with a wild type copy using gene or cell therapy based approaches [14]. However, in the case of gene therapy of DMD, this is not currently possible because dystrophin is too large to be packaged into adeno-associated viral vectors. This has led to replacement strategies that involve viral vector-mediated delivery of truncated "designer dystrophin" constructs in DMD [14]. These micro- and mini-dystrophins cause substantial improvements, but do not fully restore the dystrophic pathology and muscle function in mdx mice. Importantly, these mutant dystrophins do not restore nNOSmu [14]. Although the substantial improvement of dystrophic muscle function by mini- and micro-dystrophin suggests a minor role for nNOS in mdx pathology; the evaluation of fatigue is rarely, if ever, assayed in treated muscles despite reports of fatigue in both mice and patients [23]-[25]. Furthermore, mdx mice exhibit increased muscle mass, in contrast to Duchenne patients who suffer progressive loss of muscle mass. The present study suggests that the ability to restore nNOSmu would likely confer additional important functionality to the designer dystrophins. These data strongly argue that the restoration of sarcolemmal nNOSmu in dystrophic muscle may be more important than previously appreciated.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
###xml 15 19 <span type="species:ncbi:10090">Mice</span>
nNOS-Deficient Mice
###end title 39
###begin p 40
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nos1</italic>
###xml 13 18 13 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tmplh</sup>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS1</italic>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Huang1">[29]</xref>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
B6.129S4-Nos1tmplh/J mice purchased from The Jackson Laboratory, ME, USA were used to establish a colony. These mice are commonly known as nNOS knockout or KN1 mice and were generated by targeted disruption of exon 2 of the NOS1 gene [29]. Exon 2 encodes the PDZ domain of nNOSalpha and muscle-specific nNOSmu; therefore, the skeletal muscles of KN1 mice lack nNOSmu. All comparisons are made between sex- and age-matched littermates.
###end p 40
###begin title 41
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Situ</italic>
In Situ Contractile Function Analyses
###end title 41
###begin p 42
###xml 157 164 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003387-Dellorusso1">[17]</xref>
###xml 1186 1187 1180 1181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 1229 1230 1223 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1230 1231 1224 1225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1477 1478 1471 1472 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 1619 1620 1613 1614 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 1706 1707 1700 1701 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 1757 1758 1751 1752 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1764 1765 1758 1759 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 1818 1819 1812 1813 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1844 1845 1838 1839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 544 549 <span type="species:ncbi:10090">Mouse</span>
###xml 729 734 <span type="species:ncbi:10090">mouse</span>
All experimental procedures performed on mice were approved by the Institutional Animal Care and Use Committee of the University of Washington. We performed in situ analysis of TA muscle function with modifications as described previously [17]. This approach allows for measurement of contractile properties without removing the muscle from its natural environment, thereby maintaining normal vasoregulation and innervation. Eight week old mice were anesthetized with intraperitoneal injections of 2,2,2, tribromoethanol (Sigma, St Louis, MO). Mouse hindlimbs were shaved and the distal TA tendon of the tibialis anterior (TA) muscle was surgically isolated via a skin incision on the anterior surface of the lower hindlimb. The mouse was positioned on a 37degreesC heated platform in order to restrain the knee joint and the distal tendon was attached to the lever arm of a servomotor (Model 305B-LR, Aurora Scientific, ON, Canada). The exposed surface of the muscle was kept moist by frequent application of prewarmed isotonic saline. The TA muscle was stimulated by electrical trigger of the peroneal nerve using two needle electrodes. The muscle was adjusted to an optimum length (Lo) that produced the maximum twitch force (Pt). Then, the time to reach peak tension (TPT) during the contraction phase of the twitch, and the half-relaxation time (HRT), the time between maximum and half-maximum force during the relaxation phase of the twitch were recorded. While held at Lo the TA was stimulated every two minutes at increasing frequencies (5 to 200 Hz) to generate force-frequency curves. Maximal tetanic force (Po) generation was typically achieved at 200 Hz. After the completion of testing, both Lo and TA mass were recorded and used to normalize Pt and Po for TA muscle size and calculate specific twitch (sPt) or specific tetanic (sPo) force. The first hindlimb was used for testing resistance to exercise-induced fatigue, while the second was used to test susceptibility to contraction-induced injury.
###end p 42
###begin title 43
Resistance to Exercise-Induced Fatigue
###end title 43
###begin p 44
###xml 358 359 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 456 462 456 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;x/&#964;</sup>
To test the capacity of muscle to sustain force output, TA muscles were subjected to a series of repeated contractions to simulate exercise and cause fatigue. Muscles were subject to maximal stimulation (40 V, 200 Hz) at 2 s intervals for 4 minutes. Maximum isometric force production was recorded every 2 s. Recovery from fatigue was assessed by recording Po at 1 minute and 5 minutes after the completion of the fatigue period. Exponential curves (y = Ae-x/tau where A is the initial force (mN), x is time (s) and tau is the time constant) were fitted to the 4 minute fatigue period with Igor Pro 5 software (Wavemetrics, OR). The time constant tau (reflecting the timecourse of fatigue in seconds where a larger tau value represents a slower rate of fatigue) and the force plateau (the asymptote of the exponential curve) were calculated from these curves.
###end p 44
###begin title 45
Contraction-Induced Injury
###end title 45
###begin p 46
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
The resistance of muscles to contraction-induced injury was assessed by subjecting TA muscles to a series of consecutive lengthening contractions of progressively increased strain. Strain is the percentage increase in length beyond the optimal muscle length Lo. Muscles were maximally stimulated (4 V, 200 Hz) for 150 ms at fixed length to achieve maximal isometric tension, immediately followed by 200 ms of stimulation during the application of a length change ranging from 0 to 45% beyond Lo. Strain was applied at the rate of 2 fiber lengths/s. Lengthening contractions were performed at 30 s intervals to minimize the impact of fatigue on force-generating capacity. The maximum tetanic force generated immediately prior to the initiation of the subsequent lengthening contraction was recorded and normalized. At the conclusion of contractile function analysis, animals were sacrificed and the tibialis anterior and soleus muscles were rapidly excised and weighed.
###end p 46
###begin title 47
Statistical Analyses
###end title 47
###begin p 48
###xml 428 429 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 476 477 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The number of animals of each sex and genotype analyzed for each experimental condition are given in the figure legends. All values are reported as mean+/-SEM. Two way univariate analysis of variance (ANOVA) was used to determine the statistical significance of the effects of gender and genotype on experimental measures using SPSS software (SPSS Inc.). For all other comparisons, values were compared using unpaired Student's t-tests using Microsoft(R) Excel 2007 software. p values less than 0.05 were considered significant.
###end p 48
###begin p 49
The authors wish to thank Dr Kimberley Craven for critical reading of the manuscript and Dr Glen Banks for excellent technical assistance.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
Physiology of nitric oxide in skeletal muscle.
###end article-title 51
###begin article-title 52
Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle.
###end article-title 52
###begin article-title 53
Nitric oxide in skeletal muscle.
###end article-title 53
###begin article-title 54
Nitric oxide modulates excitation-contraction coupling in the diaphragm.
###end article-title 54
###begin article-title 55
Concerted regulation of skeletal muscle contractility by oxygen tension and endogenous nitric oxide.
###end article-title 55
###begin article-title 56
Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle.
###end article-title 56
###begin article-title 57
Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase.
###end article-title 57
###begin article-title 58
Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.
###end article-title 58
###begin article-title 59
Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains.
###end article-title 59
###begin article-title 60
Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy.
###end article-title 60
###begin article-title 61
Loss of sarcolemma nNOS in sarcoglycan-deficient muscle.
###end article-title 61
###begin article-title 62
###xml 90 98 <span type="species:ncbi:9606">children</span>
Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.
###end article-title 62
###begin article-title 63
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.
###end article-title 63
###begin article-title 64
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.
###end article-title 64
###begin article-title 65
Structural abnormalities at neuromuscular synapses lacking multiple syntrophin isoforms.
###end article-title 65
###begin article-title 66
Influence of nitric oxide on vascular resistance and muscle mechanics during tetanic contractions in situ.
###end article-title 66
###begin article-title 67
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury.
###end article-title 67
###begin article-title 68
Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy.
###end article-title 68
###begin article-title 69
###xml 72 76 <span type="species:ncbi:10090">mice</span>
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.
###end article-title 69
###begin article-title 70
Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium.
###end article-title 70
###begin article-title 71
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.
###end article-title 71
###begin article-title 72
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice.
###end article-title 72
###begin article-title 73
###xml 41 45 <span type="species:ncbi:9606">boys</span>
Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy.
###end article-title 73
###begin article-title 74
###xml 76 84 <span type="species:ncbi:9606">patients</span>
A standardized method for the evaluation of respiratory muscle endurance in patients with Duchenne muscular dystrophy.
###end article-title 74
###begin article-title 75
Functional characteristics of dystrophic skeletal muscle: insights from animal models.
###end article-title 75
###begin article-title 76
Alpha-sarcoglycan deficiency featuring exercise intolerance and myoglobinuria.
###end article-title 76
###begin article-title 77
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Novel mutations in three patients with LGMD2C with phenotypic differences.
###end article-title 77
###begin article-title 78
Targeted disruption of the neuronal nitric oxide synthase gene.
###end article-title 78
###begin article-title 79
###xml 92 96 <span type="species:ncbi:10090">mice</span>
rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.
###end article-title 79
###begin article-title 80
###xml 206 210 <span type="species:ncbi:10090">mice</span>
C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice.
###end article-title 80
###begin p 81
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 81
###begin p 82
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NIH grants NS046788 and NS33145 (S.C.F.), NIH grant U54 HD047175 (S.C.F. and J.S.C.), a Parent Project for Muscular Dystrophy Research Fellowship (J.M.P) and a MDA Development Grant (J.M.P).
###end p 82

